1. Home
  2. SRRK vs HBM Comparison

SRRK vs HBM Comparison

Compare SRRK & HBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • HBM
  • Stock Information
  • Founded
  • SRRK 2012
  • HBM 1927
  • Country
  • SRRK United States
  • HBM Canada
  • Employees
  • SRRK N/A
  • HBM N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • HBM Metal Mining
  • Sector
  • SRRK Health Care
  • HBM Basic Materials
  • Exchange
  • SRRK Nasdaq
  • HBM Nasdaq
  • Market Cap
  • SRRK 4.2B
  • HBM 3.5B
  • IPO Year
  • SRRK 2018
  • HBM N/A
  • Fundamental
  • Price
  • SRRK $37.70
  • HBM $7.09
  • Analyst Decision
  • SRRK Strong Buy
  • HBM Buy
  • Analyst Count
  • SRRK 7
  • HBM 3
  • Target Price
  • SRRK $40.43
  • HBM $11.17
  • AVG Volume (30 Days)
  • SRRK 793.4K
  • HBM 7.6M
  • Earning Date
  • SRRK 02-27-2025
  • HBM 02-19-2025
  • Dividend Yield
  • SRRK N/A
  • HBM 0.20%
  • EPS Growth
  • SRRK N/A
  • HBM N/A
  • EPS
  • SRRK N/A
  • HBM 0.20
  • Revenue
  • SRRK N/A
  • HBM $2,021,200,000.00
  • Revenue This Year
  • SRRK N/A
  • HBM $20.71
  • Revenue Next Year
  • SRRK N/A
  • HBM $10.44
  • P/E Ratio
  • SRRK N/A
  • HBM $36.61
  • Revenue Growth
  • SRRK N/A
  • HBM 19.60
  • 52 Week Low
  • SRRK $6.76
  • HBM $5.22
  • 52 Week High
  • SRRK $46.98
  • HBM $10.49
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 41.93
  • HBM 30.07
  • Support Level
  • SRRK $35.35
  • HBM $7.41
  • Resistance Level
  • SRRK $38.61
  • HBM $9.23
  • Average True Range (ATR)
  • SRRK 1.80
  • HBM 0.40
  • MACD
  • SRRK -0.16
  • HBM -0.19
  • Stochastic Oscillator
  • SRRK 34.20
  • HBM 4.00

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About HBM Hudbay Minerals Inc. (Canada)

Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The major mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, the next biggest source of revenue, to industrial customers across North America.

Share on Social Networks: